Page last updated: 2024-12-08

24,25-dihydrolanosterol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

lanostenol: RN given refers to (3beta)-isomer; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

24,25-dihydrolanosterol : A 3beta-sterol formed from lanosterol by reduction across the C-24-C-25 double bond. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID440560
CHEMBL ID4213010
CHEBI ID28113
SCHEMBL ID288306
MeSH IDM0064484

Synonyms (38)

Synonym
CHEBI:28113
lanostenol
lanost-8-en-3beta-ol
C05109
24,25-dihydrolanosterol
79-62-9
5alpha-lanost-8-en-3beta-ol
LMST01010087
24-dihydrolanosterol
4,4,14alpha-trimethyl-5alpha-cholesta-8-en-3beta-ol
(3s,10s,13r,14r,17r)-4,4,10,13,14-pentamethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,5,6,7,11,12,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-ol
(3s,5r,10s,13r,14r,17r)-4,4,10,13,14-pentamethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,5,6,7,11,12,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-ol
dihydrolanosterol
3beta-hydroxylanost-8-ene
5alpha-lanost-8-en-3 beta-ol
dihydrolanosterin
(3beta)-lanost-8-en-3-ol
9h273a8b2x ,
unii-9h273a8b2x
SCHEMBL288306
lanost-8-en-3-ol, (3.beta.)-
lanosterol, dihydro-
5.alpha.-lanost-8-en-3.beta.-ol
lanost-8-en-3.beta.-ol
4,4,14.alpha.-trimethyl-5.alpha.-cholest-8-en-3.beta.-ol
dihydrolanosterol [inci]
MBZYKEVPFYHDOH-BQNIITSRSA-N
lanost-8-en-3-ol #
lanost-8-en-3-ol
4,4,14a-trimethyl-5a-cholesta-8-en-3b-ol
Q27103510
(3s,5r,10s,13r,14r,17r)-4,4,10,13,14-pentamethyl-17-((r)-6-methylheptan-2-yl)-2,3,4,5,6,7,10,11,12,13,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-ol
MS-27601
DTXSID101000181
CHEMBL4213010
HY-122410
CS-0085117
AKOS040763665
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
3beta-sterolA sterol in which the hydroxy group at position 3 has beta- configuration.
tetracyclic triterpenoidAny triterpenoid consisting of a tetracyclic skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (34)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of lipids500463
Metabolism of steroids111135
Cholesterol biosynthesis2249
Steroid Biosynthesis2142
Smith-Lemli-Opitz Syndrome (SLOS)2142
CHILD Syndrome2142
Desmosterolosis2142
Chondrodysplasia Punctata II, X-Linked Dominant (CDPX2)2142
Lysosomal Acid Lipase Deficiency (Wolman Disease)2142
Ibandronate Action Pathway2143
Simvastatin Action Pathway2143
Pravastatin Action Pathway2143
Rosuvastatin Action Pathway2143
Alendronate Action Pathway2143
Hypercholesterolemia2142
Lovastatin Action Pathway2143
Zoledronate Action Pathway2143
Cerivastatin Action Pathway2143
Risedronate Action Pathway2143
Pamidronate Action Pathway2143
Fluvastatin Action Pathway2143
Atorvastatin Action Pathway2143
Cholesteryl Ester Storage Disease2142
Hyper-IgD Syndrome2142
Mevalonic Aciduria2142
Wolman Disease2142
Cholesterol metabolism with Bloch and Kandutsch-Russell pathways039
Kandutsch-Russell Pathway (Cholesterol Biosynthesis)930
Cholesterol metabolism214
Enterocyte cholesterol metabolism111
Cholesterol biosynthesis pathway in hepatocytes1137
cholesterol biosynthesis II (via 24,25-dihydrolanosterol)937
superpathway of cholesterol biosynthesis2178
Cholesterol biosynthesis II (via 24,25-dihydrolanosterol)117

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1656767Induction of human HMGCR-dCat-ELuc degradation expressed in HEK293 cells assessed as reduction in luciferase activity after 4 hrs by luciferase reporter assay2020Bioorganic & medicinal chemistry, 02-01, Volume: 28, Issue:3
Luciferase-based HMG-CoA reductase degradation assay for activity and selectivity profiling of oxy(lano)sterols.
AID1656771Inhibition of SREBP (unknown origin) expressed in HEK293 cells assessed as reduction in LDLr promotor activity after 24 hrs by luciferase reporter assay2020Bioorganic & medicinal chemistry, 02-01, Volume: 28, Issue:3
Luciferase-based HMG-CoA reductase degradation assay for activity and selectivity profiling of oxy(lano)sterols.
AID1386475Inhibition of alpha-crystallin B R120G mutant (unknown origin)-induced intracellular protein aggregation expressed in human HeLa cells or HLE-B3 cells at 4 uM incubated for 6 to 8 hrs by fluorescence microscopy relative to untreated control2018Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
Synthesis, Evaluation, and Structure-Activity Relationship Study of Lanosterol Derivatives To Reverse Mutant-Crystallin-Induced Protein Aggregation.
AID1386474Inhibition of alpha-crystallin B R120G mutant (unknown origin)-induced intracellular protein aggregation expressed in human HeLa cells or HLE-B3 cells at 0.4 uM incubated for 6 to 8 hrs by fluorescence microscopy relative to untreated control2018Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
Synthesis, Evaluation, and Structure-Activity Relationship Study of Lanosterol Derivatives To Reverse Mutant-Crystallin-Induced Protein Aggregation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (42)

TimeframeStudies, This Drug (%)All Drugs %
pre-199018 (42.86)18.7374
1990's8 (19.05)18.2507
2000's5 (11.90)29.6817
2010's8 (19.05)24.3611
2020's3 (7.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 15.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index15.84 (24.57)
Research Supply Index3.81 (2.92)
Research Growth Index4.46 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (15.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (2.33%)5.53%
Reviews1 (2.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other41 (95.35%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]